Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Chi-Med to Announce 2018 Half-Year Financial Results

Posted on: 29 Jun 18

LONDON, June 29, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST).

An analyst presentation will be held at 9:00 am BST (4:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at  The presentation will be available to download before the analyst presentation begins.

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm BST).  

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement.  A replay will also be available on the website shortly after each event.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1).  For more information, please visit:


Investor Enquiries 
Mark Lee, Senior Vice President,
Corporate Finance & Development
+852 2121 8200
U.K. & International Media Enquiries 
Anthony Carlisle,
Citigate Dewe Rogerson
+44 7973 611 888 (Mobile)
U.S. Based Media Enquiries 
Brad Miles, Solebury Trout+1 (917) 570 7340 (Mobile)
Susan Duffy, Solebury Trout+1 (917) 499 8887 (Mobile)
Investor Relations 
Xuan Yang, Solebury Trout+1 (415) 971 9412 (Mobile)
David Dible,
Citigate Dewe Rogerson  
+44 7967 566 919 (Mobile)
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts+44 (20) 7886 2500

Last updated on: 29/06/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.